Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Short term Debt (2020 - 2021)

BridgeBio Pharma's Short term Debt history spans 2 years, with the latest figure at $3.6 million for Q1 2021.

  • For Q1 2021, Short term Debt changed N/A year-over-year to $3.6 million; the TTM value through Mar 2021 reached $3.6 million, changed N/A, while the annual FY2020 figure was $1.5 million, N/A changed from the prior year.
  • Short term Debt for Q1 2021 was $3.6 million at BridgeBio Pharma, up from $1.5 million in the prior quarter.
  • Across five years, Short term Debt topped out at $3.6 million in Q1 2021 and bottomed at $1.5 million in Q4 2020.